Thermo Fisher Scientific
TMO

$611.33

0.73%

Market Cap: $234B

About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of end-2023 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (10%); life science solutions (23%); and lab products and services, which includes CRO services (54%).

Employees: 122,000

Industrials Measuring & Controlling Devices

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

15% more repeat investments, than reductions

Existing positions increased: 1,037 | Existing positions reduced: 904

0% less funds holding

Funds holding: 2,471 [Q1] → 2,467 (-4) [Q2]

2% less first-time investments, than exits

New positions opened: 157 | Existing positions closed: 161

1.2% less ownership

Funds ownership: 89.87% [Q1] → 88.68% (-1.2%) [Q2]

6% less capital invested

Capital invested by funds: $199B [Q1] → $187B (-$12.1B) [Q2]

10% less funds holding in top 10

Funds holding in top 10: 124 [Q1] → 111 (-13) [Q2]

35% less call options, than puts

Call options by funds: $950M | Put options by funds: $1.47B

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$600

2%

downside

Avg. target

$637

4%

upside

High target

$670

10%

upside

8 analyst ratings

7 positive

88%

1 neutral

13%

0 negative

0%

Wells Fargo Brandon Couillard 36% 1-year accuracy 4 / 11 met price target	10%upside $670	Overweight Initiated	27 Aug 2024
TD Cowen Dan Brennan 61% 1-year accuracy 17 / 28 met price target	8%upside $658	Buy Maintained	25 Jul 2024
Raymond James Andrew Cooper 89% 1-year accuracy 17 / 19 met price target	8%upside $660	Outperform Maintained	25 Jul 2024
RBC Capital Conor McNamara 39% 1-year accuracy 15 / 38 met price target	9%upside $664	Outperform Maintained	25 Jul 2024
Stifel Daniel Arias 58% 1-year accuracy 11 / 19 met price target	1%upside $615	Buy Maintained	25 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about TMO published over the past 30 days

Thermo Fisher Scientific (TMO) presents at Morgan Stanley 22nd Annual Global Healthcare Conference - Conference Call Transcript

Thermo Fisher Scientific (NYSE:TMO ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning.

Thermo Fisher Scientific (TMO) presents at Morgan Stanley 22nd Annual Global Healthcare Conference - Conference Call Transcript

Thermo Fisher Scientific to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 8:30 a.m. (EDT). You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is.

Thermo Fisher Scientific to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024

Zacks Investment Research

Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?

Zacks Investment Research

Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now

Thermo Fisher Scientific Innovations Achieve R&D 100 Awards, including Special Recognition Market Disruptor

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, has received three R&D 100 Awards for innovations that aid researchers' and scientists' work in a variety of life science applications, including proteomics, bioproduction and small-molecule analysis. Notably, the Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer (MS) won gold in the Market Disruptor special recognition category as one of the most significant advancements in mass spectr.

Thermo Fisher Scientific Innovations Achieve R&D 100 Awards, including Special Recognition Market Disruptor

Zacks Investment Research

Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma

Thermo Fisher Scientific TMO recently secured FDA's 510(k) clearance for its SeCore CDx HLA A Sequencing System for use as a companion diagnostic (CDx) alongside Adaptimmune's ADAP newly approved T-cell receptor (TCR) therapy, TECELRA (afamitresgene autoleucel). The latter is the first engineered cell therapy for a solid tumor cancer approved in the United States and the first new therapy option in more than a decade for synovial sarcoma — a rare, soft tissue cancer that most commonly impacts young adults.

Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma

FDA Grants Thermo Fisher Scientific SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its SeCore™ CDx HLA A Sequencing System has been granted 510(k) clearance by the United States Food and Drug Administration (FDA) for use as a companion diagnostic with TECELRA® (afamitresgene autoleucel), Adaptimmune's newly approved T-cell receptor (TCR) therapy for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemoth.

FDA Grants Thermo Fisher Scientific SeCore HLA Typing Kit 510(k) Clearance for Use as Companion Diagnostic with a T-Cell Receptor Therapy for Synovial Sarcoma

Thermo Fisher Scientific Introduces Novel Pre-Transplant Risk Assessment Assay

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has introduced a new pre-transplant risk assessment assay via its CLIA laboratory in Fishers, Ind., that helps assess risk of early acute rejection in kidney transplant recipients, providing data that may inform a more personalized approach to post-transplant immunosuppression management. Standardized immunosuppression protocols based on broad clinical and demographic features are a routine part.

Thermo Fisher Scientific Introduces Novel Pre-Transplant Risk Assessment Assay

Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth

There are a whole host of reasons to invest in healthcare stocks over the long term. The United States has an aging population.

Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth

3 Stocks With the Most Recent 52-Week Highs

The overall stock market has been reeling over the last week or so. The S&P 500 index and NASDAQ have fallen by 4% and 6%, respectively, since July 16 due to uncertainty regarding the future of artificial intelligence.

3 Stocks With the Most Recent 52-Week Highs

See News Rankings